STOCKS TELEGRAPH

Tag: STAB

  • Statera Biopharma Inc. (STAB) Skyrockets Over 100% After it said to Sell Rights to Naltrexone to Immune Therapeutics

    Statera Biopharma Inc. (STAB) Skyrockets Over 100% After it said to Sell Rights to Naltrexone to Immune Therapeutics

    In the after-hours trading on April 27, Statera Biopharma Inc. (STAB) stock saw a huge uptick as its shares swung up by over 100%. After falling to a new low in the regular session, STAB surged up to $0.4199 in the after hours. The stock saw unusually high volume on Wednesday which was over 529% of its average.

    Source: Harappa Education

    This uptick came after the company announced its plan to sell rights for low-dose naltrexone to Immune Therapeutics. Added to the news was the earlier downfall causing a big dip in the stock which presented STAB as a perfect fit for the rally. A dip together with the news caused investors to go wild on the stock and made its surge by 100.91%.

    STAB’s Plan for Naltrexone

    On Wednesday, the company announced it had entered into a non-binding term sheet in connection with a strategic partnership with Immune Therapeuctics, Inc. for the sale of naltrexone and met-enkephalin rights. Immune Therapeutics develops and commercializes drugs.

    Being a non-binding term sheet, the deal is contingent upon various factors including negotiation of a definitive agreement, financing of Immune Therapeutics, and customary closing conditions. Moreover, the terms of the agreement will have STAB receiver an initial upfront payment of $2 million and 5% of the issued, outstanding stock if Immune. Added to this, the company will also be eligible for payments on revenue-based milestones, new indications, regulatory approvals, royalties, etc. In exchange, Immune will have rights to any product with low-dose naltrexone as an active ingredient.

    Overall, the transaction has the potential of generating over $400 million in non-dilutive payments to the company.

    Enhancing STAB’s Potential Amid Nasdaq Non-compliance

    Failing to file its 2021 financial statement in the given period after it missed the initial deadline, STAB is in non-compliance with Nasdaq Listing Rules. The company currently has till June 20 to submit a plan for regaining compliance by October 17 of this year.

    While the company still has to submit its financials for 2021, its agreement with Immune will strengthen its financial position. The transaction has the ability to result in significant cash flow for funding the company’s programs including its new plans for the immunotherapy field.

    Conclusion

    Owing to its potentially huge deal with Immune Therapeutics on Wednesday, STAB witnessed a huge upsurge in the after hours. Investors were super excited over the company’s transaction that could yield up to $400 million in non-dilutive payments.

    However, the mammoth gain has put the stock up for corrections soon.

  • Statera Biopharma Inc. (STAB) stock Plunges Deep After Hours on a Proposed Public Offering

    On March 21, Statera Biopharma Inc. (STAB) announced a proposed underwritten public offering. Consequently, the stock took a harsh hit in the after-hours and plunged down by a further 27.65% to reach a new low.

    Source: Yahoo Finance

    The stock traded in the red during the regular session as well, declining by 7.20% at its closing price of $0.5943 per share. Intraday trading, STAB saw a high of $0.6609 and a low of $0.5753. The volume of the session was 186% above the average as 1.31 million shares exchanged hands during the session. Following the announcement, the stock plunged down to $0.4300 per share in the after hours. Thus, STAB recorded its new 52-week low in the after-hours, against the previous $0.5400 per share.

    The clinical-stage biopharmaceutical company, Statera Biopharma Inc. was founded in 2003 and is based in Fort Collins, CO. Currently, the company’s 37.47 million outstanding shares trade at a market capitalization of $23.99 million. Declining by 13.94% in the past five days, STAB stands at a year-to-date loss of 74.16%. Moreover, the stock suffered a downfall of 90.31% last year.

    STAB’s Public Offering

    On Monday, the company announced the initiation of an underwritten public offering. The offering comprises units and pre-funded units. The units are composed of one common stock share along with one warrant for buying a common stock share. And the pre-funded units consist of one pre-funded warrant for buying a common stock share and one warrant for a common stock share’s purchase.

    Furthermore, the sole book-running manager for the offering is EF Hutton, a division of Benchmark Investments.

    Additionally, the legal counsels for the offering include Anthony L.G., PLLC to STAB and Carmel, Milazzo & Feil LLP to EF Hutton.

    Preliminary Fiscal 2021 Results

    On March 08, the company announced revised and unaudited preliminary financial results for fiscal 2021 which ended on December 31, 2021.

    In fiscal 2021, the company had revenues of $1,487,036 against $0 in the prior year with an increase of 100% YOY. This increase in revenue was a result of the acquisition of ImQuest Life Science Inc. and its subsidiaries by Old Cytocom in June 2021.

    STAB had operating costs of $31,587,009 in fiscal 2021, against $19,501,668 in fiscal 2020. Thus, marking an increase of 191% YOY.

    Additionally, based on the preliminary results, the company expects positive shareholders’ equity as of 2021 year-end.

  • Statera Biopharma, Inc. (STAB) Stock Roaring Premarket Following Preliminary Financials Release.

    Statera Biopharma, Inc. (STAB) Stock Roaring Premarket Following Preliminary Financials Release.

    Statera Biopharma, Inc. (STAB) is a late-clinical biotherapeutics company focused on the development of innovative immunotherapies aiming at different diseases. The company’s toll-like receptor plays an important part in the innate immune system. The company’s clinical portfolio includes STAT-201for Crohn’s disease, Entolimod for hematological issues, STAT-401 for pancreatic carcinoma, and STAT-205 for COVID-19.

    The price of STAB stock in the regular trading on March 8, 2022, with a gain of 5.55% was $0.58. Its price significantly increased further by 4.31% at the last check in the premarket session on March 9, 2022.

    STAB: Events and Happenings

    On March 08, 2022, STAB reported its revised and preliminary financials for FY ended December 31, 2021. The revenues for the period were reported to be $1.48 million and showed a gain of 100% in comparison to the same period in 2020.

    On March 07, 2022, STAB updated on the recent progression of its next-generation research work building upon the activity of STAT-200 on TLRs to enhance the drug features and clinical advantage outside opioid receptors. On March 02, 2022, STAB announced STAT-205 pilot trials protocol submission to the FDA for treating post-acute COVID-19.

    On February 25, 2022, STAB informed the press about the additions to its BoDs team as Satish Chandran joined the company’s new director in place of Steve Barbarick, who resigned from the position and will continue in an advisory role.

    STAB: Key Financial

    On November 15, 2021, STAB released its financial statement for Q3 2021 ended September 30, 2021. Some of the key aspects are below.

    Revenue

    Revenue of $0.23 million was recorded in Q3 2021 against nil revenue in the same quarter of 2020. The company noticed a 100% gain in revenue over the year.

    EPS

    A basic and diluted net loss per share of $12.7 million or $0.47 was reported in the third quarter of 2021 compared to $5.7 million, or $1.84 in the same period in 2020.

    Conclusion

    STAB stock dipped by 74% YTD primarily due to the economic downfall globally. The current premarket stock drive is the influence of its preliminary fourth-quarter financial statement as it reported a record revenue in the quarter. The company observed a phenomenal gain in its revenue over the yearly period.

  • Statera Biopharma, Inc. (STAB) stock experiencing downfall of 16.03% – What’s the reason?

    Statera Biopharma, Inc. (STAB) saw a decrease of 16.03% in premarket because the company announced the pricing of $2.0 Million Registered Direct Offering. However, the last trading session closed at $1.31 with a decrease of 2.96%.

    $2.0 Million Registered Direct Offering by STAB – What’s up?

    STAB announced on 6th February 2022 that it had signed into a securities sales contract with a specific institutional investor to buy about $2.0 million in ordinary shares and warrants in a regulated direct offering. Moreover, the Company’s total earnings from the authorized direct offering are estimated to be around $2.0 million.

    Phase 3 Clinical Trial Protocol by STAB – What’s going on?

    On 29th December 2021, STAB announced that the company has submitted Phase 3 clinical trial protocol for STAT-201 to FDA. STAT-201 is an immune modulator that will restore mucosal healing and intestinal barrier function. With endoscopies, Phase 2 research showed proof of concept, safety, and remission in 67 percent of individuals, as well as 43 percent of genuine mucosal healing. Moreover, the experiment had no significant side effects. The FDA has also designated STAT-201 as an orphan medication for the treatment of CD in children.

    Chronic diarrhea, stomach pain, and rectal bleeding are all signs of CD. It was once thought to be a rare condition among children and adolescents. Later it was recognized as one of the most serious chronic diseases affecting children and adolescents. Nearly a third of all CD patients are under the age of 20. The signs and symptoms are unpredictably unpredictable, causing physical, emotional, and financial hardship. Despite current medications, people with CD continue to have flares, smoldering illness, or terrible side effects, necessitating the development of novel treatment alternatives.

    Now what?

    STAB has submitted the Phase 3 clinical trial plan which is a critical milestone in the research program. Furthermore, growth failure, nutrition, late puberty, and bone demineralization are frequent in children with Crohn’s Disease, in addition to the common GI symptoms. Lastly, STAT-201 has the potential to bring significant physical and emotional relief to Crohn’s Disease patients in their adolescent years.